

SRF

Margin pressure offsets revenue gain

India Equity Research | Miscellaneous

SRF's Q4FY17 top line surpassed estimate, but INR2.2bn EBITDA came 12% below estimate due to margin pressure across segments. PAT, at INR1.3bn, surpassed the INR1.2bn forecast led by forex gain. Chemical segment's FY17 margin plummeted 470bps YoY to 19% due to weak global agrochem market. However, SRF is going ahead with capex as the segment's long-term growth remains intact. In our view, earlier-than-anticipated recovery in specialty chemical segment can trigger earnings growth. But, sustained weak demand could jeopardise earnings due to margin pressure. We revise down FY18E EPS 7% due to weak margin, but revise up FY19E EPS 7% due to commissioning of packaging plant. We will monitor the global agrochemical scenario for any sign of improvement or wait for stock price correction to review our recommendation. Maintain 'HOLD' with revised TP of INR1,786 (INR1,738 earlier), based on our SOTP-based valuation.

Refrigerants boost chemical revenue; margin under pressure

Chemical revenue, at INR5.1bn, grew 12% YoY led by strong growth in refrigerants business. Global slowdown in agrochemicals remained a drag on specialty chemical as EBIT margin remained muted at 16.6% (down 660bps YoY). Management continues to focus on this segment and has committed INR7bn capex (INR2bn announced in Q4FY17) in the past 1 year. We expect chemical revenue to pick up (FY17-19E CAGR of 18.4%) and EBIT margin to rise to 23% by FY19 (19% in FY17), leading to 30% CAGR in EBIT (FY17-19). We expect a strong refrigerants segment to also support margin.

Technical textile, packaging films margins flounder

Technical textile sustained strong revenue growth of 23% YoY to INR5.3bn albeit, on a low base. Segment's margin, however, tumbled 110bps YoY to 10%. Packaging films' revenue jumped 26% YoY to INR3.8bn led by commissioning of BOPET plant in Q4FY17. However, its margin reeled under pressure due to significant capacity addition in the industry. We have modeled the same in our FY18/19E numbers. We believe, upcoming capacities in packaging films is likely to keep margins under pressure.

Outlook and valuations: recovery awaited; maintain 'HOLD'

Pick up in global agrochemical market is a key trigger for SRF. We revise down FY18E EPS 7% due to current weak margin, but revise up FY19E EPS 7% due to commissioning of the packaging film plant. Our SOTP-based valuation yields target price of INR1,786. We maintain 'HOLD' recommendation.

Financials (Consolidated)

(INR mn)

Year to March	Q4FY17	Q4FY16	YoY (%)	Q3FY17	QoQ (%)	FY17	FY18E	FY19E
Net Revenues	13,258	11,130	19.1	11,330	17.0	48,218	57,097	65,228
EBITDA	2,157	2,248	(4.0)	2,312	(6.7)	9,694	10,855	13,004
Adj. Profit	1,147	1,072	7.0	1,119	2.4	4,874	5,197	6,505
Dil. EPS (INR)	20.0	18.7	7.0	19.5	2.4	84.9	90.5	113.3
Dil. P/E (x)						19.1	17.9	14.3
EV/EBITDA (x)						11.3	10.1	8.2
ROAE (%)						16.7	15.3	16.9

EDELWEISS RATINGS

Absolute Rating	HOLD
Investment Characteristics	Growth

MARKET DATA (R: SRFL.BO, B: SRF IN)

CMP	: INR 1,617
Target Price	: INR 1,786
52-week range (INR)	: 1,970 / 1,197
Share in issue (mn)	: 57.4
M cap (INR bn/USD mn)	: 93 / 1,436
Avg. Daily Vol. BSE/NSE ('000)	: 243.9

SHARE HOLDING PATTERN (%)

	Current	Q2FY17	Q1FY17
Promoters *	52.4	52.4	52.4
MF's, FI's & BKs	10.8	10.8	11.2
FII's	18.1	18.6	18.0
Others	18.7	18.2	18.5
* Promoters pledged shares (% of share in issue)	:		NIL

PRICE PERFORMANCE (%)

	BSE Midcap Index	Stock	Stock over Index
1 month	(3.7)	(6.7)	(2.9)
3 months	5.1	4.2	(1.0)
12 months	28.4	30.9	2.5

Rohan Gupta

+91 22 4040 7416

rohan.gupta@edelweissfin.com

Sneha Talreja

+91 22 4040 7417

sneha.talreja@edelweissfin.com

May 25, 2017

Q4FY17 conference call: Key highlights

SRF expects near term challenges which includes:

- Slowdown in agrochemical sector
- Strengthening INR
- Higher tax - 30% (23-24% last year)

Chemicals

- In FY17, revenue mix was 50:50 for refrigerants: specialty chemicals, similar to FY16.
- For specialty chemicals segment, revenue remained flat YoY at INR7.5bn.
- Margin for specialty chemicals are better than refrigerants.
- Overall margin will only improve once share of specialty chemicals picks up.
- In the specialty chemicals segment, share of agri : pharma stands at 75: 25 (similar to last year).

Specialty Chemicals

Capex

- **In FY17, SRF incurred capex of INR7bn**, of which INR3bn was expended towards BOPET plant (packaging films segment) and balance for chemicals division.
- **For FY18, the company is planning capex of INR10bn** to be largely incurred on chemical division, except INR2.5bn on packaging films segment for BOPP plant.
- By FY18 year end, the company targets to maintain debt at current levels.
- During the quarter, SRF announced capex of INR2bn for chemicals segment to create production capability to produce new agrochemical with peak production capacity of 250MT and carry out modifications in the P 11/12 plant to improve capacities to meet R 134a production requirements, both at Dahej.
- The new dedicated agrochemicals plant will be JV with customer where SRF will be manufacturing active ingredient trying for the first time in agrochemicals sector. SRF and customer have worked together for 6-7 years to bring this project to reality. There will be long term lock-in with the customer for supply of this product and will take 12-18 months for commissioning of this plant

Packaging Films

- In Feb 2017, BOPET unit at Indore was commissioned.
- In FY17, 4 lines of BOPET got commissioned in including SRF's line which is adding to margin pressure.
- Margins are likely to remain under pressure.

Refrigerants

- Volume of R134 increased ~30% to 9,000 tonnes in FY17 (versus 7,000 tonnes in FY16).
- SRF continues to enjoy more than 50% market share with improving volumes and better product offerings.
- It is the first company to launch FLORON 22 cans in India this will prevent pilferage

- In next couple of weeks, SRF will be ready with its Dymel brand and it will take ~1 year for the company to switch customers from Dymel to SRF

Chart 1: C&P share stood higher at 36% in Q4FY17 from 32% in Q3FY17...






Chart 2: ...similarly share of C&P EBIT increased to 48% in Q4FY17 from 36% in Q3FY17



Source: Company, Edelweiss research

Chart 3: C&P margins fell by 660bps YoY, stable QoQ



Source: Company, Edelweiss research

Financial snapshot

(INR mn)

Year to March	Q4FY17	Q4FY16	% change	Q3FY17	% change	FY17	FY18E	FY19E
Net revenues	13,258	11,130	19.1	11,330	17.0	48,218	57,097	65,228
Staff costs	1,212	1,121	8.1	1,075	12.8	4,338	4,772	5,249
Direct costs	6,995	5,400	29.5	5,559	25.8	24,184	28,606	33,006
Other expenses	2,893	2,360	22.6	2,384	21.4	10,002	12,864	13,968
EBITDA	2,157	2,248	(4.0)	2,312	(6.7)	9,694	10,855	13,004
Depreciation	730	695	5.1	709	3.0	2,834	3,248	3,565
EBIT	1,428	1,554	(8.1)	1,604	(11.0)	6,860	7,607	9,439
Other income	259	114	128.3	64	303.3	455	500	500
Interest	228	320	(28.7)	269	(15.1)	1,018	889	777
Add: Exceptional items	185	57	225.9	(45)	(516.0)	-	-	-
Profit before tax	1,644	1,404	17.1	1,355	21.3	6,296	7,218	9,162
Provision for taxes	352	287	22.5	271	29.7	1,422	2,021	2,657
Minority interest								
Associate profit share								
Profit- Discontinued Ops								
Reported net profit	1,292	1,117	15.7	1,084	19.2	4,874	5,197	6,505
Adjusted Profit	1,147	1,072	7.0	1,119	2.4	4,874	5,197	6,505
Diluted shares (mn)	57	57		57		57	57	57
Adjusted Diluted EPS	20.0	18.7	7.0	19.5	2.4	84.9	90.5	113.3
As % of net revenues								
Direct costs	52.8	48.5		49.1		50.2	50.1	50.6
Employee cost	9.1	10.1		9.5		9.0	8.4	8.0
Other expenses	21.8	21.2		21.0		20.7	22.5	21.4
EBITDA	16.3	20.2		20.4		20.1	19.0	19.9
Reported net profit	8.6	9.6		9.9		10.1	9.1	10.0
Tax rate	21.4	20.4		20.0		22.6	28.0	29.0

Change in Estimates

	FY18E			FY19E			Comments
	New	Old	% change	New	Old	% change	
Net Revenue	57,097	52,191	9.4	65,228	58,116	12.2	Higher growth from Packaging films and Chemicals division
EBITDA	10,855	11,080	(2.0)	13,004	12,580	3.4	Revenue partially offset by cautious margin assumption in packaging and technical textiles segment
EBITDA Margin	19.0	21.2		19.9	21.6		
Adjusted Profit	5,197	5,362	(3.1)	6,505	6,033	7.8	
After Tax							
Net Profit Margin	9.1	10.3		10.0	10.4		
Capex	10,000	7,690	30.0	4,500	7,759	(42.0)	

Company Description

SRF is a multi-business entity manufacturing chemical-based industrial intermediates. It commenced operations as Shri Ram Fibres in 1970 when its parent company DCM decided to set up a separate entity to manufacture nylon tyre cord fibres. Its business portfolio covers technical textiles, fluorochemicals, chloromethanes, specialty chemicals, engineering plastics and packaging films. SRF does business with 75 countries and has 9 facilities in India and 2 each in Thailand and South Africa. The company's business is divided into 3 divisions: (1) technical textiles, (2) chemical & polymers; and (3) packaging films.

Investment Theme

Car/refrigerator sales to spur fluorochemicals; R&D to drive specialty: Capacity utilisation in SRF's fluorochemicals business is anticipated to surge riding spurt in sales of refrigerators & cars and import substitution. Moreover, R&D investments, cornerstone of SRF's commendable success in high entry barriers specialty chemicals, have yielded handsome dividends—filed 30 process patents in FY17, taking the tally to 111 patents filed till date and commercialised more than 40 products—leading to 18% revenue CAGR over FY12-17. With a strong products pipeline and focused capex (INR25bn to be incurred over 3-4 years), we expect the division to post strong revenue growth, and catapult its revenue/EBITDA share going forward.

Technical textiles: Cash cow; Packaging: Consumption growth play - SRF has been channelising technical textiles' ~INR2.2bn/year FCF to finance incremental capex in other divisions. We estimate packaging films to clock 20% revenue CAGR over FY17-19, led by capacity addition.

Key Risks

Limited product life cycle: There is a risk of early phase out of the molecule due to availability of a substitute or development of some other molecule in the other market.

Pace of launch of new molecules: SRF faces inventory risk as the timing of launch of a molecule is determined by client campaign. Also, this leads to volatility risk on quarterly basis as when a molecule is launched profitability shoots up significantly.

Financial Statements

Key assumption

Year to March	FY16	FY17	FY18E	FY19E
Macro Assumptions				
GDP(Y-o-Y %)	7.2	6.5	7.1	7.7
Inflation (Avg)	4.9	4.8	5.0	5.2
Repo rate (exit rate)	6.8	6.3	6.3	6.3
USD/INR (Avg)	65.0	67.5	67.0	67.0
Financial Assumptions				
Revenue Growth				
Technical Textile	(7)	6	2	2
Chemicals & Polymers	29.8	5.0	15.0	22.0
Packaging Films	9.2	3.6	20.0	20.0
EBIT margin (%)				
Technical Textile	9.1	12.6	11.0	11.0
Chemicals & Polymers	23.7	19.0	21.0	23.0
Packaging Films	14.2	14.0	11.5	11.5
Balance Sheet Assumptions				
Capex (INR mn)	5,876	7,014	10,000	4,500
Inventory (days)	115	116	105	95
Receivables (days)	45	44	41	38
Payable (days)	101	115	103	95

Income statement

(INR mn)

Year to March	FY16	FY17	FY18E	FY19E
Net revenue	45,927	48,218	57,097	65,228
Materials costs	23,306	24,184	28,606	33,006
Employee costs	3,863	4,338	4,772	5,249
Other Expenses	9,030	10,002	12,864	13,968
Total operating expenses	36,199	38,524	46,242	52,223
EBITDA	9,728	9,694	10,855	13,004
Depreciation	2,750	2,834	3,248	3,565
EBIT	6,979	6,860	7,607	9,439
Add: Other income	278.3	454.6	500.00	500.00
Less: Interest Expense	1,305	1,018	889	777
Profit Before Tax	5,952	6,296	7,218	9,162
Less: Provision for Tax	1,551	1,422	2,021	2,657
Reported Profit	4,402	4,874	5,197	6,505
Adjusted Profit	4,402	4,874	5,197	6,505
Shares o/s (mn)	57	57	57	57
Adjusted Basic EPS	76.7	84.9	90.5	113.3
Diluted shares o/s (mn)	57	57	57	57
Adjusted Diluted EPS	76.7	84.9	90.5	113.3
Adjusted Cash EPS	124.5	134.3	147.1	175.4
Dividend per share (DPS)	10.0	12.0	15.0	20.0
Dividend Payout Ratio(%)	15.7	17.0	19.9	20.7

Common size metrics

Year to March	FY16	FY17	FY18E	FY19E
Materials costs	50.7	50.2	50.1	50.6
Staff costs	8.4	9.0	8.4	8.0
S G & A expenses	19.7	20.7	22.5	21.4
Depreciation	6.0	5.9	5.7	5.5
Interest Expense	2.8	2.1	1.6	1.2
EBITDA margins	21.2	20.1	19.0	19.9
Net Profit margins	9.6	10.1	9.1	10.0

Growth ratios (%)

Year to March	FY16	FY17	FY18E	FY19E
Revenues	1.2	5.0	18.4	14.2
EBITDA	35.6	(0.4)	12.0	19.8
PBT	49.0	5.8	14.6	26.9
Adj. net profit	45.4	10.7	6.6	25.2
EPS	45.4	10.7	6.6	25.2

Balance sheet		(INR mn)			
As on 31st March	FY16	FY17	FY18E	FY19E	
Share capital	584	584	584	584	
Reserves & Surplus	26,110	31,242	35,406	40,567	
Shareholders' funds	26,695	31,827	35,990	41,152	
Short term borrowings	5,781	5,456	6,198	6,511	
Long term borrowings	19,120	14,319	11,586	9,023	
Total Borrowings	24,901	19,774	17,784	15,534	
Long Term Liabilities	583	596	856	978	
Deferred tax (net)	3,997	2,840	2,840	2,840	
Sources of funds	56,176	55,037	57,471	60,505	
Gross Block	69,625	75,500	86,886	91,386	
Net Block	40,151	43,193	51,331	52,265	
Capital work in progress	1,174	2,586	1,200	1,200	
Intangible Assets	988	857	857	857	
Total Fixed Assets	42,313	46,635	53,387	54,322	
Non current investments	43	251	251	251	
Cash and Equivalents	5,468	2,669	631	2,275	
Inventories	7,050	8,381	8,010	9,242	
Sundry Debtors	5,145	6,569	6,281	7,175	
Loans & Advances	4,538	566	4,355	4,975	
Other Current Assets	140	4,513	213	243	
Current Assets (ex cash)	16,873	20,029	18,858	21,635	
Trade payable	7,146	8,089	8,010	9,242	
Other Current Liab	1,376	6,458	7,647	8,736	
Total Current Liab	8,521	14,547	15,657	17,978	
Net Curr Assets-ex cash	8,351	5,482	3,201	3,657	
Uses of funds	56,176	55,037	57,471	60,505	
BVPS (INR)	464.9	554.3	626.8	716.7	

Free cash flow		(INR mn)			
Year to March	FY16	FY17	FY18E	FY19E	
Reported Profit	4,402	4,874	5,197	6,505	
Add: Depreciation	2,750	2,834	3,248	3,565	
Interest (Net of Tax)	965	788	640	551	
Others	552	(788)	(640)	(551)	
Less: Changes in WC	(2,232)	(2,882)	(2,541)	334	
Operating cash flow	10,900	10,591	10,986	9,737	
Less: Capex	5,876	7,014	10,000	4,500	
Free Cash Flow	5,024	3,577	986	5,237	

Cash flow metrics				
Year to March	FY16	FY17	FY18E	FY19E
Cash flow from ops	10,900	10,591	10,986	9,737
Investing cash flow	(6,667)	(7,222)	(10,000)	(4,500)
Financing cash flow	(1,825)	(5,953)	(3,023)	(3,594)
Net cash Flow	2,408	(2,584)	(2,037)	1,643
Capex	(5,876)	(7,014)	(10,000)	(4,500)
Dividend paid	(692)	(827)	(1,034)	(1,344)

Profitability and efficiency ratios				
Year to March	FY16	FY17	FY18E	FY19E
ROAE (%)	17.7	16.7	15.3	16.9
ROACE (%)	14.7	14.2	15.4	18.0
Inventory Days	115	116	105	95
Debtors Days	45	44	41	38
Payable Days	101	115	103	95
Cash Conversion Cycle	58	46	43	38
Current Ratio	2.6	1.6	1.2	1.3
Gross Debt/EBITDA	2.6	2.0	1.6	1.2
Gross Debt/Equity	0.9	0.6	0.5	0.4
Adjusted Debt/Equity	1.0	0.7	0.6	0.4
Net Debt/Equity	0.7	0.5	0.5	0.3
Interest Coverage Ratio	5.3	6.7	8.6	12.2

Operating ratios				
Year to March	FY16	FY17	FY18E	FY19E
Total Asset Turnover	0.9	0.9	1.0	1.1
Fixed Asset Turnover	1.1	1.1	1.2	1.2
Equity Turnover	1.8	1.6	1.7	1.7

Valuation parameters				
Year to March	FY16	FY17	FY18E	FY19E
Adj. Diluted EPS (INR)	76.7	84.9	90.5	113.3
Y-o-Y growth (%)	45.4	10.7	6.6	25.2
Adjusted Cash EPS (INR)	124.5	134.3	147.1	175.4
Diluted P/E (x)	21.1	19.0	17.9	14.3
P/B (x)	3.5	2.9	2.6	2.3
EV / Sales (x)	2.4	2.3	1.9	1.6
EV / EBITDA (x)	11.5	11.3	10.1	8.2
Dividend Yield (%)	0.6	0.7	0.9	1.2

Additional Data

Directors Data

Arun Bharat Ram	Chairman	Ashish Bharat Ram	Managing Director
Kartik Bharat Ram	Dy Managing Director	K. Ravichandra	Director
Vellayan Subbiah	Non-Executive Director	Vinayak Chatterjee	Non-Executive Director
Pramod Bhasin	Non-Executive Director	Tejpreet S. Chopra	Non-Executive Director
L. Lakshman	Non-Executive Director	Meenakshi Gopinath	Non-Executive Director

Auditors - Deloitte Haskins & Sells

**as per last available data*

Holding – Top10

	Perc. Holding		Perc. Holding
Amansa Capital	6.50	UTI Unit & Charitable & Religion	1.61
DSP Blackrock	4.07	Dimensional Fund Advisors	1.53
Stiching Dep Apq	2.01	UTI Asset Mgmt	1.24
Max New York Life Emrg Eq	1.25	Max New York Life Insurance Co	1.07
Sundaram Asset Mgmt	1.90	Kotak Mahindra	0.54

**as per latest available data*

Bulk Deals

Data	Acquired / Seller	B/S	Qty Traded	Price
No Data Available				

**as per last available data*

Insider Trades

Reporting Data	Acquired / Seller	B/S	Qty Traded
27 May 2016	Arun Bharat Ram	Buy	27500.00
27 May 2016	Karmav Real Estate Holding LLP	Sell	27500.00

**as per last available data*

Edelweiss Securities Limited, Edelweiss House, off C.S.T. Road, Kalina, Mumbai – 400 098.

Board: (91-22) 4009 4400, Email: research@edelweissfin.com

Aditya Narain

Head of Research

aditya.narain@edelweissfin.com

Coverage group(s) of stocks by primary analyst(s): Miscellaneous

AIA Engineering, Apar Industries Ltd, Aarti Industries, Agro Tech Foods, Balkrishna Industries, CCL Products India, Essel Propack, Orient Refractories, Supreme Industries, Solar Industries, SRF, Vesuvius India, VIP Industries

Recent Research

Date	Company	Title	Price (INR)	Recos
24-May-17	CCL Products India	Constrained by capacity; moving up the value chain; <i>Result Update</i>	288	Buy
22-May-17	Aarti Industries	Specialty chemicals on a high; margin pressure anticipated; <i>Result Update</i>	859	Buy
28-Apr-17	Supreme Industries	Demonetisation dents volume; product mix change drive margin; <i>Result Update</i>	1,088	Buy

Distribution of Ratings / Market Cap


Edelweiss Research Coverage Universe

	Buy	Hold	Reduce	Total
Rating Distribution*	161	67	11	240
* 1stocks under review				
	> 50bn	Between 10bn and 50 bn	< 10bn	
Market Cap (INR)	156	62	11	

Rating Interpretation

Rating	Expected to
Buy	appreciate more than 15% over a 12-month period
Hold	appreciate up to 15% over a 12-month period
Reduce	depreciate more than 5% over a 12-month period

One year price chart



DISCLAIMER

Edelweiss Securities Limited (“ESL” or “Research Entity”) is regulated by the Securities and Exchange Board of India (“SEBI”) and is licensed to carry on the business of broking, depository services and related activities. The business of ESL and its Associates (list available on www.edelweissfin.com) are organized around five broad business groups – Credit including Housing and SME Finance, Commodities, Financial Markets, Asset Management and Life Insurance.

This Report has been prepared by Edelweiss Securities Limited in the capacity of a Research Analyst having SEBI Registration No. INH200000121 and distributed as per SEBI (Research Analysts) Regulations 2014. This report does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Securities as defined in clause (h) of section 2 of the Securities Contracts (Regulation) Act, 1956 includes Financial Instruments and Currency Derivatives. The information contained herein is from publicly available data or other sources believed to be reliable. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in Securities referred to in this document (including the merits and risks involved), and should consult his own advisors to determine the merits and risks of such investment. The investment discussed or views expressed may not be suitable for all investors.

This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ESL and associates / group companies to any registration or licensing requirements within such jurisdiction. The distribution of this report in certain jurisdictions may be restricted by law, and persons in whose possession this report comes, should observe, any such restrictions. The information given in this report is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. ESL reserves the right to make modifications and alterations to this statement as may be required from time to time. ESL or any of its associates / group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. ESL is committed to providing independent and transparent recommendation to its clients. Neither ESL nor any of its associates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including loss of revenue or lost profits that may arise from or in connection with the use of the information. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. Past performance is not necessarily a guide to future performance. The disclosures of interest statements incorporated in this report are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. The information provided in these reports remains, unless otherwise stated, the copyright of ESL. All layout, design, original artwork, concepts and other Intellectual Properties, remains the property and copyright of ESL and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the copyright holders.

ESL shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, break down of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of the ESL to present the data. In no event shall ESL be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the ESL through this report.

We offer our research services to clients as well as our prospects. Though this report is disseminated to all the customers simultaneously, not all customers may receive this report at the same time. We will not treat recipients as customers by virtue of their receiving this report.

ESL and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the Securities, mentioned herein or (b) be engaged in any other transaction involving such Securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company(ies) discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance. ESL may have proprietary long/short position in the above mentioned scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider risk appetite or investment objective of any particular investor; readers are requested to take independent professional advice before investing. This should not be construed as invitation or solicitation to do business with ESL.

ESL or its associates may have received compensation from the subject company in the past 12 months. ESL or its associates may have managed or co-managed public offering of securities for the subject company in the past 12 months. ESL or its associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. ESL or its associates may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. ESL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Research analyst or his/her relative or ESL's associates may have financial interest in the subject company. ESL and/or its Group Companies, their Directors, affiliates and/or employees may have interests/ positions, financial or otherwise in the Securities/Currencies and other investment products mentioned in this report. ESL, its associates, research analyst and his/her relative may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (i) exchange rates can be volatile and are subject to large fluctuations; (ii) the value of currencies may be affected by numerous market factors, including world and national economic, political and regulatory events, events in equity and debt markets and changes in interest rates; and (iii) currencies may be subject to devaluation or government imposed exchange controls which could affect the value of the currency. Investors in securities such as ADRs and Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Research analyst has served as an officer, director or employee of subject Company: No

ESL has financial interest in the subject companies: No

ESL's Associates may have actual / beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report.

Research analyst or his/her relative has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No

ESL has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No

Subject company may have been client during twelve months preceding the date of distribution of the research report.

There were no instances of non-compliance by ESL on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years except that ESL had submitted an offer of settlement with Securities and Exchange commission, USA (SEC) and the same has been accepted by SEC without admitting or denying the findings in relation to their charges of non registration as a broker dealer.

A graph of daily closing prices of the securities is also available at www.nseindia.com

Analyst Certification:

The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Additional Disclaimers

Disclaimer for U.S. Persons

This research report is a product of Edelweiss Securities Limited, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Edelweiss Securities Limited only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Edelweiss Securities Limited has entered into an agreement with a U.S. registered broker-dealer, Edelweiss Financial Services Inc. ("EFSI"). Transactions in securities discussed in this research report should be effected through Edelweiss Financial Services Inc.

Disclaimer for U.K. Persons

The contents of this research report have not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 ("FSMA").

In the United Kingdom, this research report is being distributed only to and is directed only at (a) persons who have professional experience in matters relating to investments falling within Article 19(5) of the FSMA (Financial Promotion) Order 2005 (the "Order"); (b) persons falling within Article 49(2)(a) to (d) of the Order (including high net worth companies and unincorporated associations); and (c) any other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as "relevant persons").

This research report must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this research report relates is available only to relevant persons and will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this research report or any of its contents. This research report must not be distributed, published, reproduced or disclosed (in whole or in part) by recipients to any other person.

Disclaimer for Canadian Persons

This research report is a product of Edelweiss Securities Limited ("ESL"), which is the employer of the research analysts who have prepared the research report. The research analysts preparing the research report are resident outside the Canada and are not associated persons of any Canadian registered adviser and/or dealer and, therefore, the analysts are not subject to supervision by a Canadian registered adviser and/or dealer, and are not required to satisfy the regulatory licensing requirements of the Ontario Securities Commission, other Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and are not required to otherwise comply with Canadian rules or regulations regarding, among other things, the research analysts' business or relationship with a subject company or trading of securities by a research analyst.

This report is intended for distribution by ESL only to "Permitted Clients" (as defined in National Instrument 31-103 ("NI 31-103")) who are resident in the Province of Ontario, Canada (an "Ontario Permitted Client"). If the recipient of this report is not an Ontario Permitted Client, as specified above, then the recipient should not act upon this report and should return the report to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any Canadian person.

ESL is relying on an exemption from the adviser and/or dealer registration requirements under NI 31-103 available to certain international advisers and/or dealers. Please be advised that (i) ESL is not registered in the Province of Ontario to trade in securities nor is it registered in the Province of Ontario to provide advice with respect to securities; (ii) ESL's head office or principal place of business is located in India; (iii) all or substantially all of ESL's assets may be situated outside of Canada; (iv) there may be difficulty enforcing legal rights against ESL because of the above; and (v) the name and address of the ESL's agent for service of process in the Province of Ontario is: Bamac Services Inc., 181 Bay Street, Suite 2100, Toronto, Ontario M5J 2T3 Canada.

Disclaimer for Singapore Persons

In Singapore, this report is being distributed by Edelweiss Investment Advisors Private Limited ("EIAPL") (Co. Reg. No. 201016306H) which is a holder of a capital markets services license and an exempt financial adviser in Singapore and (ii) solely to persons who qualify as "institutional investors" or "accredited investors" as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Pursuant to regulations 33, 34, 35 and 36 of the Financial Advisers Regulations ("FAR"), sections 25, 27 and 36 of the Financial Advisers Act, Chapter 110 of Singapore shall not apply to EIAPL when providing any financial advisory services to an accredited investor (as defined in regulation 36 of the FAR. Persons in Singapore should contact EIAPL in respect of any matter arising from, or in connection with this publication/communication. This report is not suitable for private investors.

Copyright 2009 Edelweiss Research (Edelweiss Securities Ltd). All rights reserved